Download PDF
Semin intervent Radiol 2020; 37(05): 492-498
DOI: 10.1055/s-0040-171919
Review Article

Interventional Treatment of Hepatic Metastases from Colorectal Cancer

Patrick D. Sutphin
1   Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Suvranu Ganguli
2   Division of Interventional Radiology, Department of Radiology, Boston Medical Center, Boston University Medical School, Boston, Massachusetts
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Modern systemic therapies provide a significant survival benefit in metastatic colorectal cancer. Despite these advances, the durability of response remains limited and nearly all patients progress on systemic treatment. Colorectal liver metastases (CLM) develop in approximately half of patients with metastatic disease and contribute to mortality in most patients. In selected patients, surgical resection of hepatic metastases prolongs survival, indicating the benefits of the targeted treatment of CLM through alternate means. Minimally invasive interventional treatments offer the promise of treating CLM in a wider range of patients than those eligible for surgical resection. Thermal ablation and intra-arterial therapies, including chemoembolization and radioembolization, are commonly used in the treatment of CLM. Each of these treatment modalities will be discussed in detail with an emphasis on the available clinical data for each interventional treatment for CLM.

Keywords

colorectal cancer - colorectal liver metastases - ablation - radioembolization


Publication History

Article published online:
11 December 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394 (10207): 1467-1480
    CrossrefPubMedGoogle Scholar
  • 2 Petrelli F, Tomasello G, Borgonovo K. et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 2017; 3 (02) 211-219
    CrossrefPubMedGoogle Scholar
  • 3 Siegel RL, Miller KD, Goding Sauer A. et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70 (03) 145-164
    CrossrefPubMedGoogle Scholar
  • 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 5 Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014; 21 (02) 501-506
    CrossrefPubMedGoogle Scholar
  • 6 Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis 1984; 4 (02) 170-179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141 (05) 586-589
    CrossrefPubMedGoogle Scholar
  • 8 Kuipers EJ, Grady WM, Lieberman D. et al. Colorectal cancer. Nat Rev Dis Primers 2015; 1: 15065
    CrossrefPubMedGoogle Scholar
  • 9 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
    CrossrefPubMedGoogle Scholar
  • 10 Overman MJ, Lonardi S, Wong KYM. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36 (08) 773-779
    CrossrefPubMedGoogle Scholar
  • 11 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18 (09) 1182-1191
    CrossrefPubMedGoogle Scholar
  • 12 Wong SL, Mangu PB, Choti MA. et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28 (03) 493-508
    CrossrefPubMedGoogle Scholar
  • 13 Ahmed M, Solbiati L, Brace CL. et al; International Working Group on Image-guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 2014; 273 (01) 241-260
    CrossrefPubMedGoogle Scholar
  • 14 Shady W, Petre EN, Gonen M. et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes--a 10-year experience at a single center. Radiology 2016; 278 (02) 601-611
    CrossrefPubMedGoogle Scholar
  • 15 Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265 (03) 958-968
    CrossrefPubMedGoogle Scholar
  • 16 Sucandy I, Cheek S, Golas BJ, Tsung A, Geller DA, Marsh JW. Long-term survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. HPB (Oxford) 2016; 18 (09) 756-763
    CrossrefPubMedGoogle Scholar
  • 17 Ruers T, Punt C, Van Coevorden F. et al. EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23 (10) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 18 Ruers T, Van Coevorden F, Punt CJ. et al. European Organisation for Research and Treatment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017;109(09)
    PubMedGoogle Scholar
  • 19 Davidson B, Gurusamy K, Corrigan N. et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. Health Technol Assess 2020; 24 (21) 1-38
    CrossrefPubMedGoogle Scholar
  • 20 Shady W, Petre EN, Do KG. et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol 2018; 29 (02) 268-275.e1
    CrossrefPubMedGoogle Scholar
  • 21 Sotirchos VS, Petrovic LM, Gönen M. et al. Colorectal cancer liver metastases: biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology 2016; 280 (03) 949-959
    CrossrefPubMedGoogle Scholar
  • 22 Brudvik KW, Mise Y, Chung MH. et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2016; 23 (08) 2635-2643
    CrossrefPubMedGoogle Scholar
  • 23 Shady W, Petre EN, Vakiani E. et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget 2017; 8 (39) 66117-66127
    CrossrefPubMedGoogle Scholar
  • 24 Calandri M, Yamashita S, Gazzera C. et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 2018; 28 (07) 2727-2734
    CrossrefPubMedGoogle Scholar
  • 25 Wang X, Sofocleous CT, Erinjeri JP. et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013; 36 (01) 166-175
    CrossrefPubMedGoogle Scholar
  • 26 Wright RD. The blood supply of newly developed epithelial tissue in the liver. J Pathol Bacteriol 1937; 45 (02) 405-414
    CrossrefPubMedGoogle Scholar
  • 27 Bierman HR, Byron Jr RL, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 1951; 12 (01) 107-131
    PubMedGoogle Scholar
  • 28 Lang EK, Brown Jr CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189 (02) 417-422
    CrossrefPubMedGoogle Scholar
  • 29 Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009; 250 (01) 281-289
    CrossrefPubMedGoogle Scholar
  • 30 Albert M, Kiefer MV, Sun W. et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117 (02) 343-352
    CrossrefPubMedGoogle Scholar
  • 31 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32 (04) 1387-1395
    PubMedGoogle Scholar
  • 32 Aliberti C, Fiorentini G, Muzzio PC. et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31 (12) 4581-4587
    PubMedGoogle Scholar
  • 33 Boeken T, Moussa N, Pernot S. et al. Does bead size affect patient outcome in irinotecan-loaded beads chemoembolization plus systemic chemotherapy regimens for liver-dominant colorectal cancer? Results of an observational study. Cardiovasc Intervent Radiol 2020; 43 (06) 866-874
    CrossrefPubMedGoogle Scholar
  • 34 Martin RC, Joshi J, Robbins K. et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18 (01) 192-198
    CrossrefPubMedGoogle Scholar
  • 35 Fiorentini G, Sarti D, Nardella M. et al. Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study. In Vivo 2020; 34 (02) 683-686
    CrossrefPubMedGoogle Scholar
  • 36 van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
    CrossrefPubMedGoogle Scholar
  • 37 Wasan HS, Gibbs P, Sharma NK. et al. FOXFIRE Trial Investigators, SIRFLOX Trial Investigators, FOXFIRE-Global Trial Investigators. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18 (09) 1159-1171
    CrossrefPubMedGoogle Scholar
  • 38 Chauhan N, Mulcahy MF, Salem R. et al. TheraSphere Yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: protocol for the EPOCH phase 3 randomized clinical trial. JMIR Res Protoc 2019; 8 (01) e11545
    CrossrefPubMedGoogle Scholar
  • 39 Murthy R, Eng C, Krishnan S. et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 2007; 18 (12) 1588-1591
    CrossrefPubMedGoogle Scholar
  • 40 Abbott AM, Kim R, Hoffe SE. et al. Outcomes of therasphere radioembolization for colorectal metastases. Clin Colorectal Cancer 2015; 14 (03) 146-153
    CrossrefPubMedGoogle Scholar
  • 41 Damm R, Seidensticker R, Ulrich G. et al. Y90 radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer 2016; 16: 509
    CrossrefPubMedGoogle Scholar
  • 42 Hickey R, Lewandowski RJ, Prudhomme T. et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med 2016; 57 (05) 665-671
    CrossrefPubMedGoogle Scholar
  • 43 Jakobs TF, Paprottka KJ, Raeßler F. et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol 2017; 27 (01) 113-119
    CrossrefPubMedGoogle Scholar
  • 44 Kennedy A, Cohn M, Coldwell DM. et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol 2017; 8 (04) 614-624
    CrossrefPubMedGoogle Scholar
  • 45 Bester L, Meteling B, Pocock N. et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23 (01) 96-105
    CrossrefPubMedGoogle Scholar
  • 46 Seidensticker R, Denecke T, Kraus P. et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35 (05) 1066-1073
    CrossrefPubMedGoogle Scholar
  • 47 Hendlisz A, Van den Eynde M, Peeters M. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
    CrossrefPubMedGoogle Scholar
  • 48 Kalva SP, Rana RS, Liu R. et al. Yttrium-90 radioembolization as salvage therapy for liver metastases from colorectal cancer. Am J Clin Oncol 2017; 40 (03) 288-293
    CrossrefPubMedGoogle Scholar
  • 49 Narsinh KH, Van Buskirk M, Kennedy AS. et al. Hepatopulmonary shunting: a prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with 90Y radioembolization. Radiology 2017; 282 (01) 281-288
    CrossrefPubMedGoogle Scholar
  • 50 Deipolyi AR, Iafrate AJ, Zhu AX, Ergul EA, Ganguli S, Oklu R. High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival. J Vasc Interv Radiol 2014; 25 (10) 1604-1608
    CrossrefPubMedGoogle Scholar
  • 51 Gibbs P, Heinemann V, Sharma NK. et al. SIRFLOX and FOXFIRE Global Trial Investigators. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer 2018; 17 (04) e617-e629
    CrossrefPubMedGoogle Scholar
  • 52 Dabrowiecki A, Sankhla T, Shinn K. et al. Impact of genomic mutation and timing of Y90 radioembolization in colorectal liver metastases. Cardiovasc Intervent Radiol 2020; 43 (07) 1006-1014
    CrossrefPubMedGoogle Scholar
  • 53 Magnetta MJ, Ghodadra A, Lahti SJ, Xing M, Zhang D, Kim HS. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdom Radiol (NY) 2017; 42 (02) 451-459
    CrossrefPubMedGoogle Scholar